Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

The bioreductive drug tirapazamine (TPZ, SR 4233, WIN 59075) is a lead compound in a series of potent cytotoxins that selectively kill hypoxic rodent and human solid tumour cells in vitro and in vivo. Phases II and III trials have demonstrated its efficacy in combination with both fractionated radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chinje, E C, Patterson, A V, Saunders, M P, Lockyer, S D, Harris, A L, Stratford, I J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374320/
https://www.ncbi.nlm.nih.gov/pubmed/10584872
http://dx.doi.org/10.1038/sj.bjc.6690819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374320/
https://www.ncbi.nlm.nih.gov/pubmed/10584872
http://dx.doi.org/10.1038/sj.bjc.6690819

Ejemplares similares